Company
Case45
We develop zero-shot AI for oncology.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- London, United Kingdom
- Customers
- healthcare (oncology prognostic and predictive tests in unmet need), and pharma (drug development)
Claim, correct or request removal
Record updated 17 September 2026
About
Our models are rooted in cancer evolutionary biology and the tumor microenvironment, predicting outcomes and treatment response from routine histology slides. We’ve completed blinded pan-cancer validation across 14+ phase II/III trials and 30,000+ patients, all on a single model, without retraining or fine-tuning. Our tests are available today from our CAP-accredited CLIA lab in the Texas Medical Center.
Loading relationship preview